Design and setting
This retrospective cohort study and population PK analysis study
screened all adults with a medically confirmed diagnosis of CF that were
admitted at the McGill University Health Centre (MUHC), a tertiary care
facility, for the treatment of an APE between January 2015 and December
2019. Patients were included if they received IV tobramycin in the
antibiotic regimen as treatment for their APE, inhaled tobramycin
resulted in exclusion. This study was approved by MUHC ethics committee.
Tobramycin dosing regimens vary according to patient characteristics and
physician’s personnel assessment of patient severity and risk of adverse
events. All dosing regimens were included in this study. Patients who
were switched from tobramycin to another aminoglycoside or vice-versa
were also included, however, changing antibiotic was considered in the
analysis.